Organovo’s FXR Program, including FXR314
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. | Eli Lilly has acquired Organovo’s lead asset,
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
Under this transaction, Organovo will receive an upfront payment as well as milestones to be paid as FXR314 achieves key regulatory and commercial milestones. Lilly is acquiring all commercial and intellectual property rights to Organovo’s FXR program for worldwide development.
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...
Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback